As sirens blare on biotech public markets, small cell therapy player Gamida plans to axe 10% of staff

With biotech on a major slowdown and funding dried up, small biotechs are having to scramble to cover their bottom lines. In the case of a small Boston cell therapy player, that means some jobs will be on the firing line.